¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Results and problems in cell differentiation."¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
  • light cell
    ¹àÀº¼¼Æ÷
  • lipoid cell
    ÁöÁú¼¼Æ÷
  • luteal cell
    Ȳ(»ö)ü¼¼Æ÷
  • lymphoid cell
    ¸²ÇÁ°è¼¼Æ÷, ¸²ÇÁ¸ð¾ç¼¼Æ÷
  • lymphokine-activated killer cell
    ¸²Æ÷Ä«ÀÎȰ¼º»ìÇØ¼¼Æ÷
  • lymphopoietic cell
    ¸²ÇÁ±¸Çü¼º¼¼Æ÷
  • lymphosarcoma cell leukemia
    ¸²ÇÁÀ°Á¾¼¼Æ÷¹éÇ÷º´
  • lacunar cell
    °ø°£¼¼Æ÷
  • mitotic cell
    À¯»çºÐ¿­±â¼¼Æ÷
  • mitral cell
    ½Â¸ð¼¼Æ÷
  • mixed germ cell tumor
    È¥ÇÕÁ¾ÀÚ¼¼Æ÷Á¾¾ç
  • monocyte-macrophage cell system
    ´ÜÇÙ±¸Å«Æ÷½Ä¼¼Æ÷°èÅë, ´ÜÇÙ±¸´ë½Ä¼¼Æ÷°èÅë
  • mononuclear cell
    ´ÜÇÙ¼¼Æ÷, ´ÜÇÙ±¸
  • mossy cell
    À̳¢¼¼Æ÷
  • mother cell
    ¸ð¼¼Æ÷, ¾î¹Ì¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
  • neuroglial cell
    ½Å°æ¾Æ±³¼¼Æ÷
  • neurosecretory cell
    ½Å°æºÐºñ¼¼Æ÷
  • nevus cell
    ¸ð¹Ý¼¼Æ÷
  • nodal cell
    °áÀý¼¼Æ÷
  • nucleated cell
    À¯ÇÙ¼¼Æ÷
  • null cell
    ¹«Ç¥Áö¼¼Æ÷
  • nurse cell
    (¢¡supporting cell) ¹öÆÀ¼¼Æ÷
  • oat cell carcinoma
    ±Í¸®¼¼Æ÷¾ÏÁ¾
  • osmiophilic cell
    Ä£¿À½º¹Å¼¼Æ÷
  • oxyntic cell
    (¢¡parietal cell) º®¼¼Æ÷
  • oxyphilic cell
    È£»ê¼¼Æ÷
  • packed red blood cell
    ³óÃàÀûÇ÷±¸
  • parafollicular cell
    ¼ÒÆ÷°ç¼¼Æ÷
  • paralutein cell
    ȲüÁÖÀ§¼¼Æ÷, ºÎȲü¼¼Æ÷
  • parietal cell
    º®¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
  • helper T cell
    Á¶·ÂT¼¼Æ÷, º¸Á¶T¼¼Æ÷
  • helper T cell
    º¸Á¶ T¼¼Æ÷
  • helper T cell
    º¸Á¶ T ¼¼Æ÷
  • helper cell
    º¸Á¶¼¼Æ÷
  • helper cell
    Á¶·Â¼¼Æ÷, º¸Á¶¼¼Æ÷
  • helper cell activity
    Á¶·Â¼¼Æ÷´É, º¸Á¶¼¼Æ÷´É
  • hematopoietic cell transplantation
    Á¶Ç÷¼¼Æ÷À̽Ä(¡­á¬øàì¹ãÕ)
  • hematopoietic stem cell
    Á¶Ç÷°£¼¼Æ÷
  • hemolytic plaque-forming cell
    ¿ëÇ÷¹Ý Çü¼º¼¼Æ÷, ¿ëÇ÷ÇöóÅ© Çü¼º¼¼Æ÷
  • hensens cell
    ¹Ù±ù°æ°è¼¼Æ÷
  • hepatic cell
    °£¼¼Æ÷(ÊÜá¬øà).
  • hepatic cell cord
    °£¼¼Æ÷ÁÙ, °£¼¼Æ÷»è(¡­ßã).
  • heteroploid cell line
    À̼öü¼¼Æ÷°è
  • heterotrophic cell
    Á¾¼Ó¿µ¾ç¼¼Æ÷.
  • high peroxidase cell
    °íÆä·Ï½Ã´Ù¾ÆÁ¦¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
  • apical cell
    Á¤(´Ü)¼¼Æ÷(ð¢Ó®á¬øà)
  • aplasia, red cell
    ÀûÇ÷±¸ Çü¼ººÎÀü(îåúìϹû¡à÷Üôîï)
  • argentaffin chromaffin cell
    Å©·Òģȭ¼º ¼¼Æ÷
  • argyrophil(e) cell
    ÀºÄ£È­¼º ¼¼Æ÷(ëÞöÑûúàõá¬øà)
  • arsenical basal cell carcinoma
    ºñ¼Ò¼º(Ý÷áÈàõ) ±âÀú¼¼Æ÷¾Ï
  • arteritis,giant cell of aorta
    ´ëµ¿¸Æ(ÓÞÔÑØæ)ÀÇ °Å¼¼Æ÷¼º(ËÝá¬øààõ)
  • aschoff cell
    ¾Æ¼îÇÁ ¼¼Æ÷(¡­á¬øà)
  • aschoff giant cell
    ¾Æ¼îÇÁ °Å¼¼Æ÷(¡­ËÝá¬øà)
  • asymmetric cell division
    ºñ´ëμº ¼¼Æ÷ºÐ¿­
  • autoimmune disease,bypass of t-helper cell(low zone)
    T-º¸Á¶¼¼Æ÷ ³»¼º ¿ìȸ(¡­ÜÍð¾á¬øàÒ±àõéæüß)
  • autosplenectomy,in sickle cell disease
    °â»ó¼¼Æ÷º´(ÌÇßÒá¬øàÜ»)
  • axis of cell
    ¼¼Æ÷Ãà
  • b cell
    B ¼¼Æ÷(¡­á¬øà)
  • b7, in t cell anergy
    B7, T-¼¼Æ÷ ¾Æ³×¸£±â
  • bacterial cell
    ±Õü, ±Õ¼¼Æ÷.
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 18
RCA red cell agglutination; relative chemotactic activity; renal cell carcinoma; right carotid artery; r...
RCF red cell ferritin; red cell folate; relative centrifugal field/force; ristocetin cofactor
RCS rabbit aorta-contracting substance; red cell suspension; reticulum cell sarcoma; right coronary sinu...
RGC radio-gas chromatography; remnant gastric cancer; retinal ganglion cell; right giant cell
RSC rat spleen cell; rested state contraction; reversible sickle-cell; right subclavian
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 18
Ca(2+) I(Ca) and
CD(3) CDCl(3) and
CSHA Canadian Study of Health and Aging
CALGB Cancer and Leukaemia Group B
CARDIAC Cardiovascular Disease and Alimentary Comparison
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • isolated T-cell deficiency
    T ¼¼Æ÷ °áÇÌ
  • juxtaglomerular cell tumor
    ¹æ»ç±¸Ã¼ ¼¼Æ÷ Á¾¾ç
  • killer T-cell
    ¼¼Æ÷ »óÇØ¼º T ¼¼Æ÷, ¼¼Æ÷»ì¼º T ¼¼Æ÷, »ìÇØ¼º T ¼¼Æ÷, ¼¼Æ÷»ìÇØ¼º T ¼¼Æ÷
  • labile cell
    ºÒ¾ÈÁ¤ ¼¼Æ÷
  • lacrimoethmoid cell
    ´©°ñ »ç ºÀ¿Í
  • lactotropic cell
    ÇÁ·Î¶ôƾ ºÐºñ ¼¼Æ÷
    µ¿ÀǾî=lactotro
  • lacunar cell
    ¼Ò¿Í ¼¼Æ÷
    Reed-Stemberg ¼¼Æ÷ÀÇ º¯ÇüÀ¸·Î¼­ ¶Ñ·ÇÇÑ ¼¼Æ÷¸· ¾È¿¡ Á¸ÀçÇϴ dzºÎÇÑ ¼¼Æ÷Áú¿¡ µÑ·¯½ÎÀÎ ´ÜÀÏ ÇÙÀ» °¡Áö°í ÀÖ´Ù.
  • lamina IV cell
    Á¦4Ãþ ¼¼Æ÷
    1. µÕ±Û°í »ï°¢Çü ȤÀº º° ¸ð¾çÀÇ ½Å°æ ¼¼Æ÷°¡ ³ôÀº ¹Ðµµ·Î ¹è¿­µÇ¾î ÀÖ´Ù. 2. °¡º­¿î Á¢ÃË °°Àº ³·Àº ¿ªÄ¡ÀÇ Àڱؿ¡ ¹ÝÀÀÇÑ´Ù.
  • laminar I cell
    Á¦ 1Ãþ ¼¼Æ÷
    1. ÀÛ°í Áß°£ Å©±âÀÇ ¼¼Æ÷¿Í ºÐ»êµÇ¾î ÀÖ´Â Å« ¹æÃßÇüÀÇ ¼¼Æ÷µé·Î ±¸¼ºµÈ´Ù. 2. Èİ¢ÀÇ º¼·ÏÇÑ Ç¥¸é¿¡ ÆòÇàÇÏ°Ô ¹è¿­µÇ¾î ÀÖ´Ù. 3. ¿£ÄÉÆÈ¸°, ½áºê½ºÅº½º P¸¦ ÇÔÀ¯Çϰí ÀÖ´Ù.
  • laminar II cell
    Á¦ 2Ãþ ¼¼Æ÷
  • laminar ¥± cell
    Á¦ 2Ãþ ¼¼Æ÷
    Á¦ 2ÃþÀÇ ¼¼Æ÷´Â 2Á¾·ù°¡ Àִµ¥ ÃþÀÇ ¹Ù±ù ÂÊ 1/4´Â ´õ¿í ÀÛÀº ¼¼Æ÷·Î ÅëÁõ°ú ¿­¿¡ ´ëÇÑ ¼ö¿ëü¸¦ °¡Áö°í ÀÖ°í, ¾È ÂÊ 3/4´Â Á» ´õ Å« ¼¼Æ÷·Î ¹«µ¶¼ºÀÇ ±â°è¼ö¿ëü¸¦ °¡Áö°í ÀÖ´Ù.
  • Langerhans cell
    ¶û°Ô¸£Çѽº ¼¼Æ÷, Ç¥ÇÇ¼Ó Å« Æ÷½Ä¼¼Æ÷
    µ¿ÀǾî=intrae
  • large cell
    ´ë¼¼Æ÷
    ƯÁ¤ ÀÌÀ¯°¡ ÀÖ¾î
  • LE cell
    LE ¼¼Æ÷, È«¹Ý¼º ³¶Ã¢ ¼¼Æ÷
    µÕ±Û°í, ±ÕÁú·Î º¸ÀÌ´Â ºÀÀÔü¸¦ ޽ÄÇÑ ¼º¼÷ È£Áß±¸¼º ´ÙÇÙ ¹éÇ÷±¸. ±× ºÀÀÔü ÀÚü´Â ´Ù¸¥ È£Áß±¸¿¡¼­ À¯·¡µÈ °ÍÀÌ´Ù. È«¹Ý¼º ·çǪ½º¿¡ ƯÀ¯ÇÑ °ÍÀÌÁö¸¸ °áÇÕ Á¶Á÷ÀÇ À¯»çÇÑ Áúȯ¿¡¼­µµ °üÂûµÈ´Ù.
  • lingual benign giant cell tumor
    ¾ç¼º °Å´ë ¼¼Æ÷ ¼³ Á¾¾ç
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 18
outcome and process assessment Evaluation procedures that focus on both the outcome or status (outcome assessment) of the patient at the end of an episode of care - presence of symptoms, level of activity, and mortality; and the process (process assessment) - what is done for the patient diagnostically and therapeutically.
(12 Dec 1998)
task performance and analysis The detailed examination of observable activity or behaviour associated with the execution or completion of a required function or unit of work.
(12 Dec 1998)
tax equity and fiscal responsibility act Pl97-248. Title II of the act specifies "provisions relating to savings in health and income security programs." this includes changes in payment for services, benefits and premiums of medicare as well as changes in provisions under medicaid and other specific programs covered by social security. Title II includes various revenue measures.
(12 Dec 1998)
tendon sheath of abductor pollicis longus and extensor pollicis brevis muscles The synovial sheath lining the compartment of the extensor retinaculum that contains the abductor pollicis longus and extensor pollicis brevis tendons.
Synonym: vagina tendinum musculorum abductoris longi et extensoris brevis pollicis.
(05 Mar 2000)
tendon sheath of extensor digitorum and extensor indicis muscles The synovial sheath that surrounds the four tendons of the extensor digitorum muscle and the tendon of the extensor indicis deep to the extensor retinaculum.
Synonym: vagina tendinum musculorum extensoris digitorum et extensoris indicis.
(05 Mar 2000)
tetanus and gas gangrene antitoxins A mixture of antibodies obtained from animals immunised against the toxins of Clostridium tetani, C. Perfringens, and C. Septicum.
(05 Mar 2000)
third and fourth pharyngeal pouch syndrome <syndrome> Also called the digeorge syndrome (dgs), this disorder is characterised by (1) low blood calcium levels (hypocalcaemia) due to underdevelopment (hypoplasia) of the parathyroid glands which control calcium; (2) underdevelopment (hypoplasia) of the thymus, an organ behind the breastbone in which lymphocytes mature and multiply; and (3) defects of the heart involving the outflow tracts more than from the heart. most cases of dgs are due to a microdeletion in chromosome band 22q11.2. A small number of cases have defects in other chromosomes, notably 10p13. Named after the american paediatric endocrinologist angelo digeorge. Another name for dgs is hypoplasia of the thymus and parathyroids.
(12 Dec 1998)
threatened, endangered, and sensitive species formal classifications of species. Sensitive
Species for which population viability is a concern. Sensitive species are not federally designated under the Endangered Species act. The U.S. Fish and Wildlife Service, after study, makes the following designations
(05 Dec 1998)
through-and-through laceration A laceration that penetrates two surfaces of a structure, generally restricted to skin or mucosal surfaces, such as the cheek, lip, ala nasi, pinna, etc.
(05 Mar 2000)
through-and-through myocardial infarction Infarction that involves the whole thickness of the heart muscle from endocardium to epicardium.
Synonym: through-and-through myocardial infarction.
(05 Mar 2000)
thymus and parathyroids, hypoplasia of See third and fourth pharyngeal pouch syndrome.
(12 Dec 1998)
time and motion studies The observation and analysis of movements in a task with an emphasis on the amount of time required to perform the task.
(12 Dec 1998)
Eimeria of sheep and goats Eimeria ovina (arloingi), the most common and destructive species in sheep, principal losses being in young lambs; Eimeria minakolyakimovae, a highly pathogenic parasite of sheep; Eimeria parva and Eimeria pallida are frequently found but believed to be of low virulence; Eimeria faurei, Eimeria intricata, Eimeria granulosa, Eimeria ahsata, Eimeria hawkins, Eimeria gilruthi, Eimeria gonzalezi, Eimeria christenseni, Eimeria punctata, Eimeria crandallis, and Eimeria honessi, are found in sheep or goats, and are probably of low pathogenicity. All of these species invade the epithelium of the small intestine.
Synonym: coccidia of sheep and goats.
(05 Mar 2000)
to-and-fro anaesthesia Anaesthesia using of a valveless closed anaesthesia circuit in which respired gases pass back and forth through a carbon dioxide absorbent interposed between patient and respiratory reservoir bag.
(05 Mar 2000)
to-and-fro murmur Murmur heard in both systole and diastole of the heart, as in aortic stenosis and insufficiency.
Synonym: seesaw murmur.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 18
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 18
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 18
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 18
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 18
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 18
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 18
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 18
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 18
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 18
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 18
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 18
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 18
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 18
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 18
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 18
ÅëÇÕ°Ë»ö ¿Ï·á